Foximine (BSO) and intensive melphalan (L-PAM) for neuroblastoma cell lines established at relapse right after

Foximine (BSO) and intensive melphalan (L-PAM) for neuroblastoma cell lines established at relapse right after myeloablative therapy. Bone Marrow Transplant 2002; 30: 13540. 21 Bailey HH, Ripple G, Tutsch KD, Arzoomanian RZ, Alberti D, Feierabend C et al. Phase I study of continuous-infusion L-S,R-buthionine Carbonic Anhydrase review sulfoximine with intravenous melphalan. J Natl Cancer Inst 1997; 89: 1789796. 22 Smith AC, Liao JT, Page JG, Wientjes MG, Grieshaber CK. Pharmacokinetics of buthionine sulfoximine (NSC 326231) and its impact on melphalan-induced toxicity in mice. Cancer Res 1989; 49: 5385391. 23 Grigoryan RS, Yang B, Keshelava N, Barnhart JR, Reynolds CP. Flow cytometry evaluation of single-strand DNA harm in neuroblastoma cell lines applying the F7-26 monoclonal antibody. Cytometry A 2007; 71: 95160. 24 Kang MH, Kang YH, Szymanska B, Wilczynska-Kalak U, ROCK1 Storage & Stability Sheard MA, Harned TM et al. Activity of vincristine, L-ASP, and dexamethasone against acute lymphoblastic leukemia is enhanced by the BH3-mimetic ABT-737 in vitro and in vivo. Blood 2007; 110: 2057066. 25 Drexler HG, Matsuo Y. Malignant hematopoietic cell lines: in vitro models for the study of multiple myeloma and plasma cell leukemia. Leuk Res 2000; 24: 68103. 26 Grigoryan R, Keshelava N, Anderson C, Reynolds CP. In vitro testing of chemosensitivity in physiological hypoxia. Procedures Mol Med 2005; 110: 8700. 27 Chatterjee M, Honemann D, Lentzsch S, Bommert K, Sers C, Herrmann P et al. Within the presence of bone marrow stromal cells human many myeloma cells turn out to be independent on the IL-6/gp130/STAT3 pathway. Blood 2002; one hundred: 3311318. 28 Zlei M, Egert S, Wider D, Ihorst G, Wasch R, Engelhardt M. Characterization of in vitro development of various myeloma cells. Exp Hematol 2007; 35: 1550561. 29 Keshelava N, Frgala T, Krejsa J, Kalous O, Reynolds CP. DIMSCAN: a microcomputer fluorescence-based cytotoxicity assay for preclinical testing of mixture chemotherapy. Solutions Mol Med 2005; 110: 13953. 30 Frgala T, Kalous O, Proffitt RT, Reynolds CP. A fluorescence microplate cytotoxicity assay with a 4-log dynamic variety that identifies synergistic drug combinations. Mol Cancer Ther 2007; 6: 88697. 31 Kang MH, Smith MA, Morton CL, Keshelava N, Houghton PJ, Reynolds CP. National Cancer Institute pediatric preclinical testing program: model description for in vitro cytotoxicity testing. Pediatr Blood Cancer 2011; 56: 23949. 32 Pinguet F, Martel P, Fabbro M, Petit I, Canal P, Culine S et al. Pharmacokinetics of high-dose intravenous melphalan in sufferers undergoing peripheral blood hematopoietic progenitor-cell transplantation. Anticancer Res 1997; 17: 60511.ACKNOWLEDGEMENTSWe thank Drs Henderson and Fowler for help with a cryostat applied for sectioning tumors, Janet Derten for assisting together with the MetaMorph software, Charlie Linch for assisting with analytical flow cytometry, and Tito Woodburn, Heather Hall and Heather Davidson for assisting with cell culture, STR’s and mycoplasma testing. The study was supported in component by National Cancer Institute (NCI) grant CA82830. The TX-MM-030h cell line was offered by the Texas Cancer Cell Repository (TXCCR.org) with support from Cancer Prevention Investigation Institute of Texas grant RP110763. Clinical grade BSO was supplied via an NCI Fast Access to Intervention Discovery (RAID) grant to CPR.AUTHOR CONTRIBUTIONSAT and CPR developed the investigation and analyzed the information. AT wrote the manuscript and CPR edited the manuscript. HS and MHK analyzed the GSH samples.
Docetaxel (DX) is usually a.